JP6654557B2 - 構造的相補性による生物発光の活性化 - Google Patents

構造的相補性による生物発光の活性化 Download PDF

Info

Publication number
JP6654557B2
JP6654557B2 JP2016502113A JP2016502113A JP6654557B2 JP 6654557 B2 JP6654557 B2 JP 6654557B2 JP 2016502113 A JP2016502113 A JP 2016502113A JP 2016502113 A JP2016502113 A JP 2016502113A JP 6654557 B2 JP6654557 B2 JP 6654557B2
Authority
JP
Japan
Prior art keywords
luminescence
peptide
polypeptide
luminescent
nlpoly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519065A5 (https=
JP2016519065A (ja
Inventor
アンドリュー エス ディクソン
アンドリュー エス ディクソン
ランス エンセル
ランス エンセル
メアリー ホール
メアリー ホール
キース ウッド
キース ウッド
モニカ ウッド
モニカ ウッド
マリー シュウィン
マリー シュウィン
ブロック エフ ビンコウスキ
ブロック エフ ビンコウスキ
ヒシャム ゼグゾウティー
ヒシャム ゼグゾウティー
ニーディ ナス
ニーディ ナス
スブハンジャン マンダル
スブハンジャン マンダル
セッド ゴウエリ
セッド ゴウエリ
ポンチョ マイゼンハイマー
ポンチョ マイゼンハイマー
トーマス カークランド
トーマス カークランド
ジェイムズ アンク
ジェイムズ アンク
ディリープ ケイ プルックナ
ディリープ ケイ プルックナ
マシュー ロバース
マシュー ロバース
メラニー ダート
メラニー ダート
トーマス マヒレイド
トーマス マヒレイド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of JP2016519065A publication Critical patent/JP2016519065A/ja
Publication of JP2016519065A5 publication Critical patent/JP2016519065A5/ja
Application granted granted Critical
Publication of JP6654557B2 publication Critical patent/JP6654557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283—Price estimation or determination
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Recommending goods or services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • Development Economics (AREA)
  • General Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Strategic Management (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • Marketing (AREA)
  • Economics (AREA)
  • Veterinary Medicine (AREA)
JP2016502113A 2013-03-15 2014-03-13 構造的相補性による生物発光の活性化 Active JP6654557B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15
US61/791,549 2013-03-15
PCT/US2014/026354 WO2014151736A1 (en) 2013-03-15 2014-03-13 Activation of bioluminescence by structural complementation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020013133A Division JP7280842B2 (ja) 2013-03-15 2020-01-30 構造的相補性による生物発光の活性化

Publications (3)

Publication Number Publication Date
JP2016519065A JP2016519065A (ja) 2016-06-30
JP2016519065A5 JP2016519065A5 (https=) 2017-04-13
JP6654557B2 true JP6654557B2 (ja) 2020-02-26

Family

ID=51581027

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502113A Active JP6654557B2 (ja) 2013-03-15 2014-03-13 構造的相補性による生物発光の活性化
JP2020013133A Active JP7280842B2 (ja) 2013-03-15 2020-01-30 構造的相補性による生物発光の活性化
JP2023004036A Active JP7532562B2 (ja) 2013-03-15 2023-01-13 構造的相補性による生物発光の活性化
JP2024124929A Active JP7843318B2 (ja) 2013-03-15 2024-07-31 構造的相補性による生物発光の活性化

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020013133A Active JP7280842B2 (ja) 2013-03-15 2020-01-30 構造的相補性による生物発光の活性化
JP2023004036A Active JP7532562B2 (ja) 2013-03-15 2023-01-13 構造的相補性による生物発光の活性化
JP2024124929A Active JP7843318B2 (ja) 2013-03-15 2024-07-31 構造的相補性による生物発光の活性化

Country Status (15)

Country Link
US (11) US9797889B2 (https=)
EP (4) EP4169935A1 (https=)
JP (4) JP6654557B2 (https=)
KR (3) KR102675860B1 (https=)
CN (2) CN117024548A (https=)
AU (3) AU2014236949C1 (https=)
BR (1) BR112015023394B8 (https=)
CA (3) CA3249512A1 (https=)
DK (2) DK2970412T5 (https=)
ES (2) ES2926463T3 (https=)
IL (3) IL286816B (https=)
PL (2) PL3783011T3 (https=)
PT (2) PT2970412T (https=)
SG (2) SG11201507306VA (https=)
WO (1) WO2014151736A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507306VA (en) 2013-03-15 2015-10-29 Promega Corp Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
EP3254113B1 (en) * 2015-02-05 2024-10-09 Promega Corporation Luciferase-based thermal shift assays
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
WO2018075783A2 (en) * 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3395803A1 (en) 2017-04-28 2018-10-31 Institut Pasteur Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins
US11579149B2 (en) * 2017-11-01 2023-02-14 Queen's University At Kingston Hippo pathway bioluminescent biosensor
PL3759233T4 (pl) * 2018-02-26 2022-10-10 Technische Universiteit Eindhoven Bioczujnik bioluminescencyjny do wykrywania i oznaczania ilościowego biocząsteczek
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
EP3807419A4 (en) * 2018-06-12 2022-09-07 Promega Corporation MULTIPLE LUCIFERASE
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
CN112996923B (zh) 2018-10-03 2025-02-18 普洛麦格公司 用于稳定腔肠素及其类似物和衍生物的组合物和方法
WO2020113036A2 (en) 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
US20200200765A1 (en) 2018-12-04 2020-06-25 Promega Corporation Broad spectrum gpcr binding agents
EP3941195A4 (en) 2019-03-20 2023-03-22 Promega Corporation PHOTOAFFINITY PROBES
BR112021020354A2 (pt) * 2019-04-10 2021-12-14 Promega Corp Composições e métodos para detecção de analito com o uso de bioluminescência
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
CN114450326B (zh) 2019-06-24 2025-02-11 普罗美加公司 用于将生物分子递送到细胞中的改性聚胺聚合物
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
US20230031446A1 (en) * 2019-11-22 2023-02-02 The Regents Of The University Of California Split-enzyme system to detect specific dna in living cells
KR20220121816A (ko) 2019-11-27 2022-09-01 프로메가 코포레이션 다분할 루시퍼라제 펩타이드 및 폴리펩타이드
US12061202B2 (en) 2019-12-10 2024-08-13 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
EP4127148A1 (en) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Reporter system for radionuclide imaging
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
JP7677997B2 (ja) 2020-05-22 2025-05-15 プロメガ コーポレイション キナーゼターゲットエンゲージメントの増強
CN116391129A (zh) 2020-08-28 2023-07-04 普罗美加公司 针对ras蛋白的靶标接合测定法
EP4337646A4 (en) 2021-05-13 2025-05-21 Promega Corporation BIOLUMINESCENT DETECTION OF DNA SYNTHESIS
US20240252689A1 (en) * 2021-05-18 2024-08-01 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
EP4519426A2 (en) 2022-05-04 2025-03-12 Promega Corporation Split modified dehalogenase variants
US20240060059A1 (en) 2022-05-04 2024-02-22 Promega Corporation Circularly permuted dehalogenase variants
JP2025515181A (ja) 2022-05-04 2025-05-13 プロメガ コーポレイション 伸長表面ループ領域を有する修飾デハロゲナーゼ
WO2023215497A1 (en) 2022-05-04 2023-11-09 Promega Corporation Photoactivatable compounds and uses thereof
WO2024151471A1 (en) * 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
EP4700040A1 (en) * 2023-04-21 2026-02-25 Shenzhen Loggene Life Science & Technology Co., Ltd. Peptide and luminescent complex containing same
AU2024265176A1 (en) * 2023-05-04 2025-12-11 Promega Corporation Complementation-based tags and reporters for dual-modality labeling
WO2025064581A1 (en) * 2023-09-18 2025-03-27 The Brigham And Women’S Hospital, Inc. Biosensor platform for the rapid detection of analytes
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
WO2026008850A1 (en) 2024-07-04 2026-01-08 Insempra Gmbh Linear nucleic acid templates for high-efficient cell-free protein expression
WO2026008852A2 (en) 2024-07-04 2026-01-08 Insempra Gmbh Optimized media for highly efficient cell-free protein expression systems

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
WO1994009056A1 (en) 1992-10-14 1994-04-28 Sterling Winthrop Inc. Chelating polymers
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
EP1156103B1 (en) 2000-04-26 2010-08-11 Chisso Corporation Oplophorus luciferase
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
US20040115814A1 (en) * 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
EP1931787A4 (en) 2005-09-30 2010-10-20 Univ Montana State SYSTEM FOR DETECTING PROTEIN-PROTEIN INTERACTIONS
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
EP2210104A4 (en) * 2007-11-01 2011-02-23 Univ Arizona State CELL-FREE PROCEDURE FOR DETECTING PROTEIN-LIGAND INTERACTIONS
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
GB2479847B (en) 2009-02-09 2014-02-19 Jnc Corp Coelenterazine analogs and manufacturing method thereof
WO2010119721A1 (ja) 2009-04-17 2010-10-21 独立行政法人産業技術総合研究所 超高輝度で安定な人工生物発光酵素
LT3409764T (lt) 2009-05-01 2020-06-10 Promega Corporation Sintetinės oplophorus liuciferazės su sustiprinta šviesos išeiga
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
BR112013010487B1 (pt) * 2010-11-02 2021-02-02 Promega Corporation compostos de coelenterazina, kit compreendendo ditos compostos e método para detectar luminescência em uma amostra in vitro
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
AU2013359166B2 (en) * 2012-12-12 2019-09-19 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
SG11201507306VA (en) 2013-03-15 2015-10-29 Promega Corp Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags

Also Published As

Publication number Publication date
US10288605B2 (en) 2019-05-14
US9797890B2 (en) 2017-10-24
ES2926463T3 (es) 2022-10-26
US20140348747A1 (en) 2014-11-27
SG11201507306VA (en) 2015-10-29
PL2970412T3 (pl) 2022-11-14
PT2970412T (pt) 2022-09-13
US20230342826A1 (en) 2023-10-26
CN105143249A (zh) 2015-12-09
US9797889B2 (en) 2017-10-24
JP2020097597A (ja) 2020-06-25
US20180306782A1 (en) 2018-10-25
US20160282340A1 (en) 2016-09-29
DK2970412T3 (da) 2022-08-29
BR112015023394B1 (pt) 2023-08-29
CA2906063A1 (en) 2014-09-25
JP2024167207A (ja) 2024-12-03
JP2023055734A (ja) 2023-04-18
AU2014236949B2 (en) 2018-08-02
WO2014151736A1 (en) 2014-09-25
KR20210036422A (ko) 2021-04-02
AU2018256548A1 (en) 2018-11-22
EP4169935A1 (en) 2023-04-26
BR112015023394A2 (pt) 2017-11-28
KR102675860B1 (ko) 2024-06-20
EP4177261A1 (en) 2023-05-10
IL273989B (en) 2021-10-31
CA3249512A1 (en) 2026-03-02
IL273989A (en) 2020-05-31
US20180313825A1 (en) 2018-11-01
EP3783011A1 (en) 2021-02-24
EP2970412B1 (en) 2022-08-10
US20200292534A1 (en) 2020-09-17
EP3783011B1 (en) 2022-09-21
PL3783011T3 (pl) 2022-11-21
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
US20140363375A1 (en) 2014-12-11
DK3783011T5 (da) 2024-08-19
US9869670B2 (en) 2018-01-16
AU2014236949A1 (en) 2015-09-24
IL240985B (en) 2020-05-31
US12366572B2 (en) 2025-07-22
US20250022022A1 (en) 2025-01-16
US10184936B2 (en) 2019-01-22
AU2020213288B2 (en) 2022-07-07
US10107800B2 (en) 2018-10-23
JP7280842B2 (ja) 2023-05-24
JP7843318B2 (ja) 2026-04-09
US20250045806A1 (en) 2025-02-06
KR20150129721A (ko) 2015-11-20
AU2014236949C1 (en) 2018-11-29
US20180095074A1 (en) 2018-04-05
BR112015023394B8 (pt) 2023-09-26
SG10201601929YA (en) 2016-04-28
US12367513B2 (en) 2025-07-22
CN117024548A (zh) 2023-11-10
US11493504B2 (en) 2022-11-08
US20180196038A1 (en) 2018-07-12
DK3783011T3 (da) 2022-10-17
ES2929362T3 (es) 2022-11-28
AU2018256548B2 (en) 2020-05-14
CA2906063C (en) 2025-10-07
EP2970412A4 (en) 2016-07-27
IL286816B (en) 2022-09-01
EP2970412A1 (en) 2016-01-20
CA3254603A1 (en) 2026-02-19
PT3783011T (pt) 2022-10-26
JP7532562B2 (ja) 2024-08-13
US10648971B2 (en) 2020-05-12
JP2016519065A (ja) 2016-06-30
KR20230079494A (ko) 2023-06-07
IL240985A0 (en) 2015-11-30
AU2020213288A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7843318B2 (ja) 構造的相補性による生物発光の活性化

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200130

R150 Certificate of patent or registration of utility model

Ref document number: 6654557

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250